Annual Book Value
$169.76 M
$164.96 M-35.76%
31 December 2023
Summary:
Rhythm Pharmaceuticals annual book value is currently $169.76 million, with the most recent change of +$164.96 million (-35.76%) on 31 December 2023. During the last 3 years, it has risen by +$3.23 million (+1.94%). RYTM annual book value is now -40.26% below its all-time high of $284.15 million, reached on 31 December 2021.RYTM Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Book Value
$11.21 M
-$28.13 M-71.49%
30 September 2024
Summary:
Rhythm Pharmaceuticals quarterly book value is currently $11.21 million, with the most recent change of -$28.13 million (-71.49%) on 30 September 2024. Over the past year, it has dropped by -$186.26 million (-94.32%). RYTM quarterly book value is now -97.06% below its all-time high of $380.95 million, reached on 31 March 2021.RYTM Quarterly Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RYTM Book Value Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -35.8% | -94.3% |
3 y3 years | +1.9% | -96.5% |
5 y5 years | -31.1% | -92.5% |
RYTM Book Value High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -40.3% | +1.9% | -96.5% | at low |
5 y | 5 years | -40.3% | +1.9% | -97.1% | at low |
alltime | all time | -40.3% | +619.1% | -97.1% | +121.6% |
Rhythm Pharmaceuticals Book Value History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $11.21 M(-71.5%) |
June 2024 | - | $39.34 M(-36.1%) |
Mar 2024 | - | $61.58 M(-63.7%) |
Dec 2023 | $169.76 M(-35.8%) | $169.76 M(-14.0%) |
Sept 2023 | - | $197.47 M(+8.3%) |
June 2023 | - | $182.28 M(-17.1%) |
Mar 2023 | - | $219.76 M(-16.8%) |
Dec 2022 | $264.26 M(-7.0%) | $264.26 M(-6.0%) |
Sept 2022 | - | $281.19 M(+43.7%) |
June 2022 | - | $195.63 M(-17.0%) |
Mar 2022 | - | $235.77 M(-17.0%) |
Dec 2021 | $284.15 M(+70.6%) | $284.15 M(-11.8%) |
Sept 2021 | - | $322.26 M(-8.4%) |
June 2021 | - | $351.69 M(-7.7%) |
Mar 2021 | - | $380.95 M(+128.8%) |
Dec 2020 | $166.53 M | $166.53 M(-15.4%) |
Date | Annual | Quarterly |
---|---|---|
Sept 2020 | - | $196.94 M(-12.8%) |
June 2020 | - | $225.75 M(-10.8%) |
Mar 2020 | - | $253.10 M(-9.9%) |
Dec 2019 | $281.02 M(+14.1%) | $281.02 M(+88.5%) |
Sept 2019 | - | $149.12 M(-17.8%) |
June 2019 | - | $181.47 M(-17.7%) |
Mar 2019 | - | $220.49 M(-10.5%) |
Dec 2018 | $246.26 M(+70.1%) | $246.26 M(-8.7%) |
Sept 2018 | - | $269.64 M(-5.2%) |
June 2018 | - | $284.32 M(+112.7%) |
Mar 2018 | - | $133.66 M(-7.7%) |
Dec 2017 | $144.79 M(-542.7%) | $144.79 M(-378.8%) |
Sept 2017 | - | -$51.94 M(-245.2%) |
June 2017 | - | $35.77 M(-209.4%) |
Dec 2016 | -$32.70 M(+308.8%) | -$32.70 M |
Dec 2015 | -$8.00 M | - |
FAQ
- What is Rhythm Pharmaceuticals annual book value?
- What is the all time high annual book value for Rhythm Pharmaceuticals?
- What is Rhythm Pharmaceuticals annual book value year-on-year change?
- What is Rhythm Pharmaceuticals quarterly book value?
- What is the all time high quarterly book value for Rhythm Pharmaceuticals?
- What is Rhythm Pharmaceuticals quarterly book value year-on-year change?
What is Rhythm Pharmaceuticals annual book value?
The current annual book value of RYTM is $169.76 M
What is the all time high annual book value for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals all-time high annual book value is $284.15 M
What is Rhythm Pharmaceuticals annual book value year-on-year change?
Over the past year, RYTM annual book value has changed by -$94.50 M (-35.76%)
What is Rhythm Pharmaceuticals quarterly book value?
The current quarterly book value of RYTM is $11.21 M
What is the all time high quarterly book value for Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals all-time high quarterly book value is $380.95 M
What is Rhythm Pharmaceuticals quarterly book value year-on-year change?
Over the past year, RYTM quarterly book value has changed by -$186.26 M (-94.32%)